Olema Pharmaceuticals (OLMA) Assets Average (2021 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Assets Average of $532.0 million for Q1 2026, up 23.64% year-over-year from $430.3 million in Q1 2025, and up 20.11% quarter-over-quarter from $442.9 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Assets Average (2021 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Assets Average for 6 consecutive years, with $532.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 23.64% year-over-year to $532.0 million; the TTM figure through Mar 2026 stood at $532.0 million (up 23.64% YoY), while the FY2025 annual figure was $492.2 million, up 35.24% from the prior year.
- Assets Average improved to $532.0 million in Q1 2026 per OLMA's latest filing, from $442.9 million in the prior quarter.
- Across five years, Assets Average topped out at $532.0 million in Q1 2026 and bottomed at $186.7 million in Q2 2023.
- Historically, Assets Average has averaged $306.4 million across 5 years, with a median of $270.3 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average declined 29.28% — and 2025, when it soared 59.19%.
- Olema Pharmaceuticals' Assets Average stood at $223.8 million in 2022, then advanced by 27.28% to $284.9 million in 2023, then climbed by 19.55% to $340.6 million in 2024, then surged by 30.06% to $442.9 million in 2025, then advanced by 20.11% to $532.0 million in 2026.
- Business Quant data shows OLMA's Assets Average at $532.0 million in Q1 2026, $442.9 million in Q4 2025, and $367.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 508.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 508.61 Mn |
| Mar 31, 2026 | 532.04 Mn |
| Dec 31, 2025 | 442.94 Mn |
| Sep 30, 2025 | 367.23 Mn |
| Jun 30, 2025 | 395.82 Mn |
| Mar 31, 2025 | 430.31 Mn |
| Dec 31, 2024 | 340.58 Mn |
| Sep 30, 2024 | 242.37 Mn |
| Jun 30, 2024 | 259.13 Mn |
| Mar 31, 2024 | 270.32 Mn |
| Dec 31, 2023 | 284.87 Mn |
| Sep 30, 2023 | 235.21 Mn |
| Jun 30, 2023 | 186.70 Mn |
| Mar 31, 2023 | 205.71 Mn |
| Dec 31, 2022 | 223.82 Mn |
| Sep 30, 2022 | 241.30 Mn |
| Jun 30, 2022 | 264.01 Mn |
| Mar 31, 2022 | 286.68 Mn |
| Dec 31, 2021 | 302.87 Mn |
| Sep 30, 2021 | 316.01 Mn |